Transparency in Action: FDA Comments on Pirfenidone
This article was originally published in RPM Report
Executive Summary
While FDA's proposed transparency initiative is still under discussion, there are signs that the agency is already taking a more liberal view of its disclosure polices. InterMune's pirfenidone is a case in point.